Investors in PepGen Inc. Get Chance to Lead Securities Fraud Lawsuit

Investors Urged to Act on PepGen Inc. Securities Fraud Litigation



The time is crucial for investors in PepGen Inc. (NASDAQ: PEPG) as the Rosen Law Firm, a recognized global advocate for investor rights, has reminded them of their opportunity to participate in a class action lawsuit regarding alleged securities fraud. The reminder comes for those who purchased PepGen securities between March 7, 2024, and March 3, 2025. This period is critical as it marks the timeline of potential misconduct by the company during which investors may have suffered losses.

The Rosen Law Firm has flagged August 8, 2025, as an important deadline for those who wish to take on the role of lead plaintiff in this lawsuit. Investors who purchased shares during the specified class period could be eligible for compensation without incurring any out-of-pocket expenses. This is possible through a contingency fee arrangement, a familiar practice in lawsuits where attorneys only get paid if the case is won.

What You Need to Know


Potential plaintiffs are encouraged to act swiftly. To join the class action, individuals can visit the firm’s website or call Phillip Kim, Esq., directly for further information. It's important to note that a class action lawsuit has already been filed, and those desiring to serve as lead plaintiff must submit their intentions by the deadline. Serving as a lead plaintiff means representing other investors and guiding the litigation process, which can significantly impact the outcome of the case.

Rosen Law Firm stresses the importance of selecting qualified legal counsel with a proven track record in leading such cases. This is particularly vital as many firms that promote themselves may not possess the necessary resources or recognition in the industry. The Rosen Law Firm is particularly esteemed for its achievements, including the largest settlement against a Chinese company to date and being ranked as a top firm by ISS Securities Class Action Services for numerous settlements since 2013.

Background on the Allegations


The core of the lawsuit rests on assertions that during the class action period, PepGen became involved in misleading statements regarding the effectiveness and safety of its product, PGN-EDO51. The lawsuit claims that crucial information was either misrepresented or omitted entirely, raising substantial concerns over the safety parameters for a related clinical study, termed the CONNECT2 study.

According to the filed complaint, the alleged misrepresentations included:
1. PGN-EDO51 was suggested to be more effective and safer than it truly is.
2. There were serious deficiencies in the CONNECT2 study that could potentially jeopardize its approval by the U.S. Food and Drug Administration (FDA).
3. Due to the aforementioned issues, PepGen was likely to discontinue the CONNECT2 study and, as a consequence, had overstated the clinical, regulatory, and commercial prospects of PGN-EDO51.

What Lies Ahead


As investors wait for the next steps, it's important to highlight that no class has yet been certified which means that investors are not represented unless they retain counsel. Those wishing to remain passive (absent class members) are also allowed to exercise that option. However, being part of the lead plaintiff group may provide claimants with a better strategy for potential recovery.

As the deadline approaches, investors are encouraged to observe updates, whether through following the Rosen Law Firm on platforms such as LinkedIn or Twitter, or seeking guidance directly from legal representatives. The firm emphasizes its commitment to representing investors globally and its foundational focus on securities class actions and derivative litigation.

Rosen Law Firm's previous successful settlements total hundreds of millions for investors, including over $438 million in just 2019. This track record adds an extra layer of reassurance for investors contemplating joining the class action. This could be an opportunity for affected investors to recover their losses while holding PepGen accountable for its alleged misdeeds.

Topics Financial Services & Investing)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.